Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Pretty weak financial results growth rate 8.9% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (11.9%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield -3.1% (LTM)
  • Share price is 16.8% higher than minimum and 8.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.5x vs 18.8x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.7%)165.86
year average price 156.73  


year start price 164.14 2024-08-02

min close price 142.06 2025-01-10

max close price 169.56 2025-07-24

current price 165.86 2025-08-01
Common stocks: 2 631 399 832

Dividend Yield:  3.0%
FCF Yield LTM: -3.1%
EV / LTM EBITDA: 13.5x
EV / EBITDA annualized: 14.0x
Last revenue growth (y/y):  +5.8%
Last growth of EBITDA (y/y):  +12.0%
Historical revenue growth:  +0.6%
Historical growth of EBITDA:  +23.3%
EV / Sales: 5.2x
Margin (EBITDA LTM / Revenue): 38.4%

Target EV / EBITDA (hist percentile): 18.8x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 438 312
Net Debt ($m): 31 881
EV (Enterprise Value): 470 193
EBITDA LTM (млн $): 34 804
EV / LTM EBITDA: 13.5x
Price to Book: 6.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-27247wallst.com

3 Top Dividend Kings I'm Planning on Buying

2025-07-25reuters.com

US FDA says J&J's Ethicon issues correction related to surgical stapler

2025-07-24zacks.com

Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

2025-07-23marketbeat.com

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

2025-07-22seekingalpha.com

Johnson & Johnson Stock Could Be Waking Up

2025-07-21zacks.com

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

2025-07-21zacks.com

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

2025-07-18zacks.com

J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?

2025-07-18proactiveinvestors.com

Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary

2025-07-17youtube.com

JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406
fillingDate 2024-10-23 2024-07-25 2024-05-01 2024-02-16 2023-10-27 2023-07-31 2023-04-28 2023-02-16 2022-10-27
acceptedDate 2024-10-23 16:02:27 2024-07-25 16:02:29 2024-05-01 07:09:36 2024-02-16 16:12:22 2023-10-27 16:11:34 2023-07-31 16:06:04 2023-04-28 16:07:02 2023-02-16 16:01:53 2022-10-27 16:02:59
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 22 471M 22 447M 21 383M 21 391M 21 345M 25 530M 24 746M 23 706M 23 791M
costOfRevenue 6 963M 6 869M 6 511M 6 996M 6 504M 8 212M 8 395M 7 765M 7 807M
grossProfit 15 508M 15 578M 14 872M 14 395M 14 841M 17 318M 16 351M 15 941M 15 984M
grossProfitRatio 0.69 0.694 0.696 0.673 0.695 0.678 0.661 0.672 0.672
researchAndDevelopmentExpenses 4 952M 3 440M 3 542M 4 473M 3 442M 3 829M 3 612M 4 014M 3 597M
generalAndAdministrativeExpenses 0 5 481M 5 057M 5 310M 0 0 5 738M 0 0
sellingAndMarketingExpenses 0 0 0 500M 0 0 400M 0 0
sellingGeneralAndAdministrativeExpenses 5 278M 5 481M 5 057M 5 810M 5 400M 6 665M 6 138M 6 512M 6 089M
otherExpenses 0 400M 200M 400M 400M 60M -7 228M 0 0
operatingExpenses 10 427M 8 921M 8 599M 10 283M 8 842M 10 494M 9 750M 10 526M 9 686M
costAndExpenses 17 210M 15 790M 15 110M 17 279M 15 346M 18 706M 18 145M 18 291M 17 493M
interestIncome 292M 395M 364M 363M 374M 369M 235M 254M 150M
interestExpense 193M 270M 155M 235M 264M 207M 215M 177M 51M
depreciationAndAmortization 1 846M 1 782M 1 815M 1 843M 1 829M 1 934M 1 880M 1 772M 1 685M
ebitda 5 484M 8 476M 8 648M 5 955M 7 828M 6 969M 6 731M 5 499M 7 558M
ebitdaratio 0.244 0.413 0.404 0.278 0.367 0.273 0.272 0.232 0.318
operatingIncome 2 694M 7 499M 6 833M 4 112M 5 999M 6 847M 6 621M 3 727M 6 298M
operatingIncomeRatio 0.12 0.334 0.32 0.192 0.281 0.268 0.268 0.157 0.265
totalOtherIncomeExpensesNet 644M -909M -2 189M 714M -782M -85M -7 358M 474M -476M
incomeBeforeTax 3 338M 5 748M 3 714M 4 826M 5 217M 6 762M -737M 4 201M 5 822M
incomeBeforeTaxRatio 0.149 0.256 0.174 0.226 0.244 0.265 -0.03 0.177 0.245
incomeTaxExpense 644M 1 062M 459M 694M 908M 1 618M -669M 681M 1 364M
netIncome 2 694M 4 686M 3 255M 4 049M 26 028M 5 144M -68M 3 520M 4 458M
netIncomeRatio 0.12 0.209 0.152 0.189 1.219 0.201 -0.003 0.148 0.187
eps 1.12 1.95 1.35 1.68 10.81 1.98 -0.026 1.35 1.696
epsdiluted 1.11 1.93 1.34 1.67 10.21 1.96 -0.026 1.33 1.68
weightedAverageShsOut 2 407M 2 407M 2 408M 2 407M 2 407M 2 599M 2 606M 2 614M 2 617M
weightedAverageShsOutDil 2 428M 2 422M 2 430M 2 431M 2 550M 2 626M 2 606M 2 664M 2 661M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406
fillingDate 2024-10-23 2024-07-25 2024-05-01 2024-02-16 2023-10-27 2023-07-31 2023-04-28 2023-02-16 2022-10-27
acceptedDate 2024-10-23 16:02:27 2024-07-25 16:02:29 2024-05-01 07:09:36 2024-02-16 16:12:22 2023-10-27 16:11:34 2023-07-31 16:06:04 2023-04-28 16:07:02 2023-02-16 16:01:53 2022-10-27 16:02:59
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 19 980M 24 878M 25 473M 21 859M 19 728M 21 183M 19 170M 14 127M 11 355M
shortTermInvestments 317M 597M 745M 1 068M 3 783M 7 322M 5 443M 9 392M 22 724M
cashAndShortTermInvestments 20 297M 25 475M 26 218M 22 927M 23 511M 28 505M 24 613M 23 519M 34 079M
netReceivables 16 174M 15 794M 14 946M 14 873M 14 798M 16 777M 16 350M 16 160M 15 890M
inventory 12 603M 12 169M 11 383M 11 181M 11 198M 12 888M 12 809M 12 483M 11 675M
otherCurrentAssets 4 175M 4 379M 4 455M 4 514M 4 196M 2 397M 10 616M 3 132M 3 592M
totalCurrentAssets 53 249M 57 817M 57 002M 53 495M 53 703M 60 567M 64 388M 55 294M 65 236M
propertyPlantEquipmentNet 20 479M 19 748M 19 632M 20 898M 18 821M 20 576M 20 174M 19 803M 18 152M
goodwill 44 799M 44 250M 36 616M 36 558M 36 124M 45 440M 45 575M 45 231M 33 383M
intangibleAssets 39 490M 39 725M 34 286M 34 175M 35 021M 46 246M 47 448M 48 325M 40 336M
goodwillAndIntangibleAssets 84 289M 83 975M 70 902M 70 733M 71 145M 91 686M 93 023M 93 556M 73 719M
longTermInvestments 0 1 143M 0 4 473M 4 023M 0 0 0 0
taxAssets 9 349M 9 004M 10 305M 9 279M 9 259M 8 779M 8 817M 9 123M 9 392M
otherNonCurrentAssets 10 921M 9 401M 14 125M 8 680M 9 110M 10 078M 9 567M 9 602M 8 625M
totalNonCurrentAssets 125 038M 123 271M 114 964M 114 063M 112 358M 131 119M 131 581M 132 084M 109 888M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 178 287M 181 088M 171 966M 167 558M 166 061M 191 686M 195 969M 187 378M 175 124M
accountPayables 8 954M 8 848M 8 174M 9 632M 8 355M 10 443M 9 909M 11 703M 10 153M
shortTermDebt 4 462M 9 855M 8 550M 3 451M 3 870M 11 701M 17 979M 12 771M 4 424M
taxPayables 4 834M 4 309M 3 318M 2 993M 2 899M 2 687M 4 266M 2 127M 1 986M
deferredRevenue 0 4 309M 0 2 993M 2 899M 2 687M 0 0 0
otherCurrentLiabilities 33 509M 30 921M 28 683M 30 206M 29 246M 29 339M 32 485M 31 328M 30 966M
totalCurrentLiabilities 51 759M 53 933M 48 725M 46 282M 44 370M 54 170M 60 373M 55 802M 45 543M
longTermDebt 31 289M 31 636M 25 082M 25 881M 26 051M 33 901M 34 928M 26 888M 27 603M
deferredRevenueNonCurrent 0 0 0 1 100M 0 8 997M 0 0 0
deferredTaxLiabilitiesNonCurrent 2 952M 2 635M 3 172M 3 193M 2 623M 3 627M 4 417M 6 374M 4 946M
otherNonCurrentLiabilities 22 129M 21 346M 24 967M 22 328M 21 789M 14 582M 25 382M 21 510M 40 405M
totalNonCurrentLiabilities 56 370M 55 617M 53 221M 52 502M 50 463M 61 107M 64 727M 54 772M 54 982M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 1 100M 0 0 0 0 0
totalLiabilities 108 129M 109 550M 101 946M 98 784M 94 833M 115 277M 125 100M 110 574M 100 525M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 3 120M 3 120M 3 120M 3 120M 3 120M 3 120M 3 120M 3 120M 3 120M
retainedEarnings 155 179M 155 360M 153 378M 153 843M 152 536M 129 381M 124 558M 128 345M 127 917M
accumulatedOtherComprehensiveIncomeLoss -12 522M -11 253M -10 768M -12 527M -8 780M -13 135M -12 626M -12 967M -15 292M
othertotalStockholdersEquity -75 619M -75 689M -75 710M -75 662M -75 648M -44 217M -44 183M -41 694M -41 146M
totalStockholdersEquity 70 158M 71 538M 70 020M 68 774M 71 228M 75 149M 70 869M 76 804M 74 599M
totalEquity 70 158M 71 538M 70 020M 68 774M 71 228M 76 409M 70 869M 76 804M 74 599M
totalLiabilitiesAndStockholdersEquity 178 287M 181 088M 171 966M 167 558M 166 061M 191 686M 195 969M 187 378M 175 124M
minorityInterest 0 0 0 0 0 1 260M 0 0 0
totalLiabilitiesAndTotalEquity 178 287M 181 088M 171 966M 167 558M 166 061M 191 686M 195 969M 187 378M 175 124M
totalInvestments 317M 597M 745M 5 541M 7 806M 7 322M 5 443M 9 392M 22 724M
totalDebt 35 751M 41 491M 33 632M 30 432M 29 921M 45 602M 52 907M 39 659M 32 027M
netDebt 15 771M 16 613M 8 159M 8 573M 10 193M 24 419M 33 737M 25 532M 20 672M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ JNJ
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406 200 406
fillingDate 2024-10-23 2024-07-25 2024-05-01 2024-02-16 2023-10-27 2023-07-31 2023-04-28 2023-02-16 2022-10-27
acceptedDate 2024-10-23 16:02:27 2024-07-25 16:02:29 2024-05-01 07:09:36 2024-02-16 16:12:22 2023-10-27 16:11:34 2023-07-31 16:06:04 2023-04-28 16:07:02 2023-02-16 16:01:53 2022-10-27 16:02:59
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 2 694M 4 686M 3 255M 4 132M 4 309M 5 144M -68M 3 520M 4 458M
depreciationAndAmortization 1 846M 1 782M 1 815M 1 843M 1 829M 1 934M 1 880M 1 772M 1 685M
deferredIncomeTax 90M -695M -1 562M -2 412M 560M -799M -1 543M 825M -139M
stockBasedCompensation 295M 341M 302M 178M 296M 382M 306M 213M 281M
changeInWorkingCapital 1 829M -452M -338M 3 247M -602M -2 401M 2 263M -1 239M -30M
accountsReceivables -96M -884M -279M 227M -252M -545M -54M 301M -205M
inventory -299M -391M -348M 124M -706M -217M -524M -650M -620M
accountsPayables 0 2 932M -2 483M 1 682M 1 725M 0 -2 572M 0 0
otherWorkingCapital 2 224M -2 109M 2 772M 1 214M -1 369M -1 639M 3 150M -890M 795M
otherNonCashItems 1 239M 2 219M 7 227M 875M 1 097M -78M 419M 259M 29M
netCashProvidedByOperatingActivities 7 993M 5 633M 3 657M 7 863M 7 489M 4 182M 3 257M 5 350M 6 284M
investmentsInPropertyPlantAndEquipment -1 836M -976M -807M -1 589M -967M -1 124M -863M -1 587M -952M
acquisitionsNet -338M -12 633M -1 601M 121M 121M 0 252M -17 130M 1 000 000
purchasesOfInvestments -280M -554M -630M -925M -293M -6 712M -3 774M -1 221M -9 105M
salesMaturitiesOfInvestments 466M 727M 979M 3 603M 3 910M 4 111M 7 766M 15 285M 8 690M
otherInvestingActivites -1 140M -251M 1 595M -2 412M -230M -51M -66M 256M -335M
netCashUsedForInvestingActivites -3 128M -13 687M -464M -1 202M 2 541M -3 776M 3 315M -4 397M -1 701M
debtRepayment -7 401M 11 543M -4 374M -1 096M -15 468M -8 224M -5 888M -1 743M -2 608M
commonStockIssued 0 0 195M 187M 8 700M 5 633M -11M 0 0
commonStockRepurchased -539M -136M -1 475M -216M -920M -381M -3 537M -1 320M -2 165M
dividendsPaid -2 985M -2 985M -2 869M -2 865M -2 871M -3 092M -2 942M -2 954M -2 970M
otherFinancingActivites 1 043M -878M 321M -665M -758M 73M 18 516M 7 717M 3 818M
netCashUsedProvidedByFinancingActivities -9 882M 7 544M 546M -4 655M -11 317M -5 991M 6 138M 1 700M -3 925M
effectOfForexChangesOnCash 119M -85M -125M 125M -168M -97M 28M 119M -286M
netChangeInCash -4 898M -595M 3 614M 2 131M -1 455M -5 682M 12 738M 2 772M 372M
cashAtEndOfPeriod 19 980M 24 878M 25 473M 21 859M 19 728M 21 183M 26 865M 14 127M 11 355M
cashAtBeginningOfPeriod 24 878M 25 473M 21 859M 19 728M 21 183M 26 865M 14 127M 11 355M 10 983M
operatingCashFlow 7 993M 5 633M 3 657M 7 863M 7 489M 4 182M 3 257M 5 350M 6 284M
capitalExpenditure -2 279M -976M -807M -1 589M -967M -1 124M -863M -1 587M -952M
freeCashFlow 5 714M 4 657M 2 850M 6 274M 6 522M 3 058M 2 394M 3 763M 5 332M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-15 ET (fiscal 2024 q3)
2024 q2
2024-07-17 ET (fiscal 2024 q2)
2024 q1
2024-04-16 ET (fiscal 2024 q1)
2023 q4
2024-01-23 ET (fiscal 2023 q4)
2023 q3
2023-10-17 ET (fiscal 2023 q3)
2023 q2
2023-07-20 ET (fiscal 2023 q2)
2023 q1
2023-04-18 ET (fiscal 2023 q1)
2022 q4
2023-01-24 ET (fiscal 2022 q4)
2022 q3
2022-10-18 ET (fiscal 2022 q3)
2022 q2
2022-07-19 ET (fiscal 2022 q2)
2022 q1
2022-04-19 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-15 12:00 ET
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
2024-10-15 10:25 ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
2024-10-15 10:20 ET
Johnson & Johnson Reports Q3 2024 Results
2024-10-10 20:30 ET
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
2024-10-10 12:00 ET
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
2024-10-09 12:00 ET
Johnson & Johnson Completes Acquisition of V-Wave
2024-10-04 20:30 ET
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
2024-10-02 13:00 ET
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
2024-09-30 20:05 ET
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-30 12:05 ET
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
2024-09-27 20:30 ET
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
2024-09-27 17:05 ET
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
2024-09-27 17:00 ET
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-27 12:05 ET
Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary d...
2024-09-27 12:00 ET
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
2024-09-20 22:53 ET
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
2024-09-20 19:43 ET
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
2024-09-19 22:54 ET
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
2024-09-16 06:50 ET
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
2024-09-15 06:30 ET
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
2024-09-14 13:45 ET
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
2024-09-14 07:10 ET
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
2024-09-11 22:22 ET
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
2024-09-10 21:15 ET
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
2024-09-08 17:47 ET
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
2024-09-05 20:30 ET
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2024-08-29 12:00 ET
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
2024-08-27 12:00 ET
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
2024-08-26 12:00 ET
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
2024-08-20 11:30 ET
Johnson & Johnson to Acquire V-Wave
2024-08-20 11:00 ET
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
2024-08-13 13:00 ET
Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy
2024-08-07 21:00 ET
Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
2024-08-02 12:02 ET
DePuy Synthes Launches its First Active Spine Robotics and Navigation Platform
2024-07-30 22:42 ET
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
2024-07-29 20:00 ET
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
2024-07-26 13:38 ET
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
2024-07-26 13:05 ET
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
2024-07-23 20:00 ET
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-22 15:59 ET
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
2024-07-22 12:00 ET
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
2024-07-17 10:25 ET
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
2024-07-17 10:20 ET
Johnson & Johnson reports Q2 2024 results
2024-07-11 11:30 ET
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
2024-07-02 11:30 ET
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
2024-06-28 15:30 ET
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
2024-06-27 22:46 ET
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
2024-06-21 11:30 ET
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
2024-06-20 20:30 ET
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
2024-06-20 12:00 ET
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
2024-06-17 21:55 ET
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
2024-06-17 12:00 ET
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
2024-06-15 07:30 ET
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
2024-06-14 12:00 ET
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
2024-06-12 18:26 ET
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy
2024-06-07 12:02 ET
DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures
2024-06-04 20:30 ET
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2024-05-31 12:45 ET
Johnson & Johnson Completes Acquisition of Shockwave Medical
2024-05-29 21:48 ET
Sarepta Therapeutics Set to Join S&P MidCap 400
2024-05-28 11:35 ET
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
2024-05-28 11:30 ET
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
2024-05-22 16:05 ET
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation
2024-05-16 11:30 ET
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
2024-05-13 10:46 ET
Kenvue Announces Launch of Secondary Offering
2024-05-08 20:30 ET
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-01 10:30 ET
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
2024-04-22 20:30 ET
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
2024-04-16 10:25 ET
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
2024-04-16 10:20 ET
Johnson & Johnson Reports Q1 2024 Results
2024-04-08 22:06 ET
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
2024-04-06 03:21 ET
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
2024-04-05 10:31 ET
Johnson & Johnson to Acquire Shockwave Medical
2024-04-04 22:01 ET
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
2024-04-02 20:30 ET
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
2024-03-11 20:30 ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
2024-03-07 13:33 ET
Johnson & Johnson Completes Acquisition of Ambrx
2024-03-01 20:59 ET
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2024-02-20 21:26 ET
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
2024-02-14 21:30 ET
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-02-12 21:10 ET
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
2024-02-02 21:10 ET
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-01-23 11:20 ET
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
2024-01-08 12:30 ET
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
2024-01-02 13:00 ET
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
2023-12-13 14:21 ET
Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic
2023-12-11 21:15 ET
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2023-12-07 21:15 ET
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 15:42 ET
Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy Birchfield
2023-12-05 12:15 ET
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
2023-11-30 21:30 ET
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
2023-11-30 13:40 ET
Johnson & Johnson MedTech Acquires Laminar, Inc.
2023-11-29 14:25 ET
CLASS ACTION LAWSUIT FILED AGAINST KENVUE INC. (NYSE: KVUE)
2023-11-17 17:05 ET
Talc Lawyer: Johnson & Johnson Settlements Undermine Bankruptcy Strategy, Serve as Acknowledgment That Baby Powder Contained Asbestos
2023-11-16 12:30 ET
Johnson & Johnson to Host Enterprise Business Review
2023-11-09 12:00 ET
MustGrow to Present at the Harbor Access Global SMID Cap Investor Conference November 16th
2023-11-02 23:18 ET
Key Lawyer in Johnson & Johnson Talc Litigation Supports Call to Rethink Legal Strategies in Light of Failure of Texas Two-Step
2023-10-30 16:42 ET
Cancer Victims Support Sen. Richard Blumenthal in Urging Johnson & Johnson to Accept Responsibility
2023-10-23 20:15 ET
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
2023-10-19 17:43 ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023
2023-10-17 10:20 ET
Johnson & Johnson Reports Q3 2023 Results
2023-09-18 20:30 ET
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2023-09-14 14:00 ET
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
2023-09-06 11:00 ET
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
2023-08-30 10:30 ET
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
2023-08-23 10:20 ET
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
2023-08-22 14:24 ET
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-21 10:20 ET
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
2023-08-16 22:52 ET
Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.
2023-08-09 22:42 ET
Kenvue Set to Join S&P 500
2023-08-07 23:29 ET
Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference
2023-08-04 12:00 ET
Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
2023-07-31 19:07 ET
Nachawati Law Group Trial Lawyers Renew Commitment to Cancer Victims After Judge’s Rejection of Johnson & Johnson’s Proposed $8.9B Settlement
2023-07-24 12:00 ET
Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias
2023-07-24 10:22 ET
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
2023-07-24 10:18 ET
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
2023-07-20 10:20 ET
Johnson & Johnson Reports Q2 2023 Results
2023-07-10 20:30 ET
Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit
2023-06-06 20:30 ET
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2023-05-23 15:54 ET
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
2023-05-10 20:30 ET
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-03 23:22 ET
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering
2023-04-25 20:30 ET
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference
2023-04-24 20:27 ET
Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow
2023-04-21 15:51 ET
Plaintiffs' Attorneys Representing Talc-Cancer Victims Form Ad Hoc Committee to Support J&J Settlement
2023-04-18 10:20 ET
Johnson & Johnson Reports Q1 2023 Results
2023-04-04 21:35 ET
Nachawati Law Group: Victims, Johnson & Johnson Reach Multibillion-Dollar Resolution of Talc-Cancer Lawsuits  
2023-04-04 20:10 ET
Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims
2023-04-04 16:33 ET
Beasley Allen/Arnold & Itkin Law Firms: On Eve of J&J Bankruptcy Dismissal, Cancer Victims Prepare to Enter Civil Court System
2023-03-22 20:27 ET
Talc Plaintiffs Will Press to Reopen Courthouse Doors
2023-03-15 20:30 ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
2023-03-15 16:00 ET
Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature
2023-03-08 23:12 ET
Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.
2023-02-23 10:00 ET
BioLargo Inc. (OTC:BLGO): Here Are Latest News & Developments
2023-02-14 21:30 ET
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors
2023-02-14 13:42 ET
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
2023-02-13 21:30 ET
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
2023-02-02 21:30 ET
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
2023-01-30 22:04 ET
Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
2023-01-30 19:00 ET
Third Circuit Ruling Reopens Courthouse Doors for Talc-Asbestos Claims
2023-01-18 21:30 ET
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference
2022-12-22 13:50 ET
Johnson & Johnson Completes Acquisition of Abiomed
2022-12-13 21:30 ET
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2022-12-07 21:30 ET
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-11-30 22:00 ET
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
2022-11-10 09:00 ET
Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair
2022-10-26 12:00 ET
Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in ACUVUE® OASYS MAX 1-DAY Contact Lenses
2022-10-20 11:32 ET
DePuy Synthes Receives FDA Clearance for TELIGEN™ System
2022-10-18 10:25 ET
Johnson & Johnson Reports Q3 2022 Results
2022-10-03 20:30 ET
Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference
2022-09-28 12:00 ET
Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
2022-09-28 12:00 ET
Johnson & Johnson Vision Expands Access to Myopia Management for More Patients with Abiliti™ Overnight Lenses
2022-09-28 11:45 ET
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
2022-09-20 10:30 ET
Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area
2022-09-15 11:02 ET
MustGrow and Global Partners Drive Biological Programs Forward
2022-09-14 10:30 ET
Johnson & Johnson Announces $5 Billion Share Repurchase Program
2022-09-13 20:30 ET
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2022-09-12 12:00 ET
Johnson & Johnson Vision Launches New Contact Lens Innovation to Help Meet the Needs of Digitally Intense Lifestyles: ACUVUE® OASYS MAX 1-Day
2022-09-01 09:10 ET
aCommerce and Johnson & Johnson Launch Sustainable Packaging Solution for a Better E-commerce Future in the Philippines
2022-08-24 10:30 ET
Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company
2022-08-12 20:45 ET
Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science
2022-08-09 20:30 ET
Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-08 22:45 ET
Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
2022-08-02 20:30 ET
Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference
2022-07-18 13:20 ET
Johnson & Johnson’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022
2022-06-21 00:00 ET
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
2022-06-15 12:00 ET
Johnson & Johnson Vision on Track for Multinational Launch of New Contact Lens Innovation: ACUVUE® OASYS MAX 1-Day
2022-06-08 12:00 ET
Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments
2022-06-06 12:44 ET
Johnson & Johnson to Acquire Midlands Management Corporation's Wholesale Brokerage & Binding and Managing General Underwriting Divisions
2022-05-12 20:30 ET
Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
2022-05-11 10:30 ET
Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
2022-05-04 12:00 ET
Johnson & Johnson Vision Named a Winner of Fast Company's 2022 World Changing Ideas Awards for ACUVUE® Theravision™ with Ketotifen
2022-05-02 20:30 ET
Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference
2022-04-25 11:30 ET
Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
2022-04-20 20:30 ET
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
2022-04-20 11:00 ET
MustGrow and Janssen PMP, A Division of Janssen Pharmaceutica NV, Form Exclusive Global Partnership
2022-04-19 10:25 ET
Johnson & Johnson Reports Q1 2022 Results
2022-04-19 10:20 ET
Johnson & Johnson Announces Dividend Increase of 6.6%
2022-04-07 20:30 ET
Johnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference
2022-03-25 11:15 ET
Johnson & Johnson Consumer Health Unveils New Skin Health Research at 2022 American Academy of Dermatology Meeting
2022-03-16 12:00 ET
DePuy Synthes Further Reimagines Knee Restoration with the Addition of Two New Innovations to the ATTUNE™ Knee Portfolio
2022-03-15 12:20 ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
2022-03-09 16:05 ET
Talc-Cancer Lawsuits Play Critical Role in Exposing Johnson & Johnson's Unethical Experiments on Prisoners
2022-03-02 13:00 ET
Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen - World's First and Only Drug-Eluting Contact Lens
2022-03-01 11:22 ET
Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease
2022-02-15 21:30 ET
Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors
2022-02-09 21:28 ET
Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference
2022-02-07 21:51 ET
Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference
2022-01-27 22:28 ET
Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference
2022-01-25 11:25 ET
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
2022-01-06 21:10 ET
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
2022-01-04 13:00 ET
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2022
2021-12-30 11:30 ET
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
2021-12-15 13:32 ET
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
2021-12-10 18:39 ET
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2021-12-09 22:00 ET
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
2021-12-09 11:30 ET
Johnson & Johnson Appoints Senior Leaders to Executive Committee
2021-12-05 22:03 ET
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
2021-12-04 00:24 ET
Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021
2021-11-22 21:05 ET
DePuy Synthes Launches the UNIUM™ System as a Next Generation Power Tools System for Trauma and Small Bone Procedures
2021-11-12 11:30 ET
Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business
2021-11-10 22:14 ET
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer
2021-11-09 21:30 ET
Johnson & Johnson Endows Research!America Outstanding Achievement in Public Health Awards
2021-10-21 23:48 ET
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
2021-10-21 18:38 ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021
2021-10-20 22:38 ET
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
2021-10-19 10:25 ET
Johnson & Johnson Reports Q3 2021 Results
2021-10-15 20:11 ET
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
2021-10-15 02:38 ET
Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme
2021-10-14 21:55 ET
Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
2021-10-13 10:45 ET
Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
2021-10-12 20:15 ET
Johnson & Johnson Announces Jessica Moore as Vice President of Investor Relations
2021-10-12 10:45 ET
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
2021-10-11 20:45 ET
Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference
2021-10-06 15:00 ET
Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature
2021-10-05 10:30 ET
Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
2021-09-28 11:00 ET
Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
2021-09-21 10:30 ET
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
2021-09-16 21:54 ET
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2021-09-16 12:00 ET
Johnson & Johnson Vision Announces New Collaboration to Eliminate Inequities and Increase Representation of People of Color in the Eye Care Industry
2021-09-13 22:30 ET
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
2021-09-02 20:07 ET
Battle Against Johnson & Johnson "Texas Two-Step" Ploy Moves to New Jersey
2021-08-31 17:03 ET
Outcry Continues to Grow for Johnson & Johnson to Resolve Talc-Cancer Claims After Latest Jury Verdict
2021-08-31 10:45 ET
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
2021-08-26 20:30 ET
/C O R R E C T I O N -- Johnson & Johnson/
2021-08-26 13:15 ET
Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference
2021-08-25 20:47 ET
DePuy Synthes to Showcase Innovation Momentum at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
2021-08-25 11:00 ET
Contakt World to Offer Vaccine Passport and Verification Platform To Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App
2021-08-25 10:45 ET
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
2021-08-24 21:40 ET
Ovarian Cancer Victims Ask Court to Block Johnson & Johnson's 'Texas Two-Step' Bankruptcy Plan
2021-08-19 21:18 ET
Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022
2021-08-18 12:30 ET
DePuy Synthes Introduces the INHANCE™ Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System
2021-08-12 13:14 ET
Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-09 13:07 ET
Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
2021-07-29 15:14 ET
Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney
2021-07-27 20:10 ET
Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference
2021-07-24 12:30 ET
New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery
2021-07-23 12:00 ET
Johnson & Johnson Vision Introduces VERITAS Vision System With Features To Address Key Unmet Needs In Cataract Surgery
2021-07-21 10:25 ET
Johnson & Johnson Reports Q2 2021 Results
2021-07-20 12:54 ET
Johnson & Johnson Vision Presents Scientific Data Validating Improved Surgical Outcomes With Latest Cataract Innovations And Legacy MGD Treatment At The 2021 ASCRS•ASOA Annual Meeting
2021-07-19 16:35 ET
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2021
2021-07-19 01:18 ET
Lawyers for Ovarian Cancer Victims Call on Regulators to Stop 'Contemptible' Johnson & Johnson Bankruptcy Plan
2021-07-15 17:32 ET
Johnson & Johnson Faces Class-Action Lawsuit Over Benzene-Tainted Neutrogena and Aveeno Sunscreen Products
2021-07-14 21:00 ET
Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene
2021-07-01 23:59 ET
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
2021-06-23 20:28 ET
Johnson & Johnson Vision Brings TECNIS Synergy And TECNIS Synergy Toric II PC-IOLS To North America For Cataract Patients
2021-06-09 14:59 ET
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2021-06-09 12:30 ET
Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities
2021-06-02 12:00 ET
Johnson & Johnson Vision Expands "Sight For Kids" Program to Bring Eye Care to More Children and Unveils New "Vision for Good" Community Impact Report
2021-05-24 20:30 ET
Johnson & Johnson to Host Live ESG Investor Update Webcast
2021-05-13 12:00 ET
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
2021-05-12 12:00 ET
Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management
2021-05-06 22:55 ET
Johnson & Johnson Vision Announces The Approval Of TECNIS Synergy™ And TECNIS Synergy™ Toric II IOLs In The U.S. And TECNIS Synergy™ Toric II IOLs In Canada
2021-04-27 12:00 ET
Johnson & Johnson Vision Receives Approval in Canada for World's First and Only Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE® Theravision™ with Ketotifen
2021-04-23 23:38 ET
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
2021-04-21 12:00 ET
Johnson & Johnson Vision Introduces ACUVUE® Abiliti™ to Address the Growing Prevalence and Progression of Myopia in Children
2021-04-21 08:00 ET
Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Next-Generation Phacoemulsification Machine, VERITAS™ Vision System
2021-04-20 15:54 ET
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review
2021-04-20 10:30 ET
Johnson & Johnson Reports 2021 First-Quarter Results:
2021-04-20 10:30 ET
Johnson & Johnson Announces Dividend Increase of 5.0%
2021-04-07 08:00 ET
Johnson & Johnson Vision Announces Global Collaboration with Menicon to Bring Forward Contact Lenses to Help Manage the Progression of Myopia in Children
2021-04-06 20:00 ET
Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee
2021-03-29 07:09 ET
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
2021-03-24 12:00 ET
Johnson & Johnson Vision Receives Approval of World's First and Only Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE® Theravision™ with Ketotifen
2021-03-20 01:00 ET
Jicheng Lyu: The Philanthropic Prophet
2021-03-15 12:00 ET
Johnson & Johnson Vision Introduces New ACUVUE® OASYS MULTIFOCAL with PUPIL OPTIMIZED DESIGN and Expands the ACUVUE® OASYS Portfolio of Offerings for Patients with Presbyopia
2021-03-12 16:16 ET
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
2021-03-11 16:29 ET
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
2021-03-11 13:21 ET
Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
2021-02-28 21:39 ET
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
2021-02-28 00:10 ET
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
2021-02-26 22:43 ET
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
2021-02-19 12:30 ET
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
2021-02-09 13:00 ET
Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search
2021-02-04 22:35 ET
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
2021-02-02 13:00 ET
Johnson & Johnson Vision Receives FDA Approval For Next Generation Monofocal Intraocular Lens - TECNIS Eyhance™ And TECNIS Eyhance™ Toric II IOLs - For The Treatment Of Cataract Patients
2021-01-29 13:00 ET
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
2021-01-26 11:42 ET
Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results
2021-01-21 13:00 ET
Auris Health Announces Publication of Results from BENEFIT Study of MONARCH® Platform in CHEST
2021-01-04 13:30 ET
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2021
2020-12-03 21:05 ET
Johnson & Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its Board of Directors
2020-12-01 13:00 ET
New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Options
2020-11-17 13:00 ET
Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color
2020-11-14 14:34 ET
Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
2020-11-13 12:30 ET
Wayfair Names Michael E. Sneed to its Board of Directors
2020-11-06 13:30 ET
Johnson & Johnson to Host Virtual Medical Devices Update
2020-10-22 18:16 ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2020
2020-10-13 10:39 ET
Johnson & Johnson Reports 2020 Third-Quarter Results
2020-10-08 11:50 ET
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate
2020-10-06 12:00 ET
New Survey on Eye Health Finds Most People Say They Know the Importance of an Annual Eye Exam, but - They Actually Don't and They're Not Getting One
2020-10-01 15:36 ET
Veteran Johnson & Johnson Executive Dr. Ajit Shetty Joins PreveCeutical
2020-10-01 12:40 ET
Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.
2020-09-23 10:45 ET
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
2020-09-03 13:26 ET
Johnson & Johnson Innovation and Johnson & Johnson Consumer Health China Launch the Skincare of the Future QuickFire Challenge
2020-08-29 07:30 ET
TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress
2020-08-20 13:21 ET
Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative
2020-08-19 10:30 ET
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
2020-08-05 12:30 ET
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
2020-07-30 12:30 ET
U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology
2020-07-30 09:30 ET
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
2020-07-24 11:15 ET
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
2020-07-20 17:40 ET
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020
2020-07-16 10:40 ET
Johnson & Johnson Reports 2020 Second-Quarter Results:
2020-07-06 15:58 ET
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
2020-06-10 13:25 ET
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
2020-06-04 20:47 ET
Johnson & Johnson to Host Annual Health for Humanity Investor Webcast
2020-05-28 17:44 ET
Johnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference
2020-05-18 20:01 ET
Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio
2020-04-27 22:44 ET
Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound
2020-04-23 22:51 ET
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
2020-04-14 10:31 ET
Johnson & Johnson Reports 2020 First-Quarter Results
2020-04-14 10:30 ET
Johnson & Johnson Announces Dividend Increase of 6.3%
2020-04-03 13:00 ET
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
2020-04-01 20:45 ET
Johnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus
2020-03-31 21:55 ET
Johnson & Johnson to Host Virtual Annual Meeting of Shareholders
2020-03-30 11:22 ET
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
2020-03-17 20:13 ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
2020-03-13 13:41 ET
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development
2020-03-09 10:30 ET
New GeoMap Tools Get Patient Recruitment Back on Track During the COVID-19 Outbreak
2020-02-26 20:14 ET
Johnson & Johnson to Participate in Barclays Global Healthcare Conference
2020-02-25 13:25 ET
Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
2020-02-18 14:30 ET
Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
2020-02-12 22:16 ET
Johnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-11 21:30 ET
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
2020-01-29 13:48 ET
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
2020-01-22 11:30 ET
Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:
2020-01-10 21:00 ET
Janssen Expands Research & Development Presence with Major Investment in South San Francisco
2020-01-06 14:00 ET
Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science
2019-12-30 21:05 ET
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
2019-12-20 11:45 ET
Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.
2019-12-19 16:40 ET
Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference
2019-12-08 13:00 ET
Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak
2019-12-05 21:34 ET
Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors
2019-12-03 22:39 ET
Company Investigation Confirms No Asbestos in Johnson's Baby Powder
2019-11-19 09:00 ET
Johnson & Johnson Vision Announces National Availability of ACUVUE OASYS with Transitions Light Intelligent Technology in the UK
2019-10-31 13:31 ET
Thinking about buying stock in Advanced Micro Devices, Bank of America, Electronic Arts, Johnson & Johnson, or Verizon?
2019-10-31 06:30 ET
Johnson & Johnson Vision Launches TECNIS Eyhance™ Monofocal Intraocular Lens in India
2019-10-23 13:31 ET
Thinking about trading options or stock in Apple, Boeing, Hasbro, Johnson & Johnson, or NVIDIA?
2019-10-18 12:38 ET
Johnson & Johnson Consumer Inc. To Voluntarily Recall A Single Lot Of Johnson's Baby Powder In The United States
2019-10-17 15:45 ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019
2019-04-16 12:38 ET
PlacementTracker Publishes Q1 2019 PIPE and Private Placement Markets League Tables
2019-04-15 00:00 ET
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
2019-03-28 12:30 ET
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
2019-03-20 10:00 ET
WEED, Inc. Signs First-of-its-Kind Agreement on Key Cannabis-Related Intellectual Property in Israel
2019-03-19 14:53 ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
2019-03-18 12:30 ET
XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
2019-03-12 20:30 ET
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
2019-03-11 20:30 ET
XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
2019-03-11 12:00 ET
New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
2019-03-07 11:00 ET
WEED, Inc. Signs First-of-its-Kind Agreement on Key Cannabis-Related Intellectual Property in Israel
2019-01-17 13:30 ET
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention

SEC forms

Show financial reports only

SEC form 10
2025-07-24 20:04 ET
Johnson & Johnson reported for 2025 q2
SEC form 8
2025-07-16 12:06 ET
Johnson & Johnson published news for 2025 q2
SEC form 8
2025-07-16 12:06 ET
Johnson & Johnson published news for 2025 q2
SEC form 8
2025-07-16 12:06 ET
Johnson & Johnson reported for 2025 q2
SEC form 10
2025-04-23 20:04 ET
Johnson & Johnson published news for 2025 q1
SEC form 10
2025-04-23 00:00 ET
Johnson & Johnson reported for 2025 q1
SEC form 8
2025-04-15 12:14 ET
Johnson & Johnson published news for 2025 q1
SEC form 8
2025-04-15 12:14 ET
Johnson & Johnson published news for 2025 q1
SEC form 8
2025-04-15 12:14 ET
Johnson & Johnson reported for 2025 q1
SEC form 8
2025-04-15 12:14 ET
Johnson & Johnson published news for 2025 q1
SEC form 8
2025-04-03 20:43 ET
Johnson & Johnson published news for 2025 q1
SEC form 8
2025-04-03 20:43 ET
Johnson & Johnson published news for 2025 q1
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-26 21:23 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-02-20 22:26 ET
Johnson & Johnson published news for 2024 q4
SEC form 10
2025-02-13 21:07 ET
Johnson & Johnson published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Johnson & Johnson reported for 2024 q4
SEC form 8
2025-01-22 06:35 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-01-22 06:35 ET
Johnson & Johnson published news for 2024 q4
SEC form 8
2025-01-22 06:35 ET
Johnson & Johnson reported for 2024 q4
SEC form 10
2024-10-23 00:00 ET
Johnson & Johnson reported for 2024 q3
SEC form 8
2024-10-15 07:37 ET
Johnson & Johnson published news for 2024 q3
SEC form 8
2024-10-15 07:37 ET
Johnson & Johnson published news for 2024 q3
SEC form 8
2024-10-15 07:37 ET
Johnson & Johnson reported for 2024 q3
SEC form 10
2024-07-25 00:00 ET
Johnson & Johnson reported for 2024 q2
SEC form 8
2024-07-17 08:14 ET
Johnson & Johnson published news for 2024 q2
SEC form 8
2024-07-17 08:14 ET
Johnson & Johnson published news for 2024 q2
SEC form 8
2024-07-17 08:14 ET
Johnson & Johnson reported for 2024 q2
SEC form 10
2024-05-01 00:00 ET
Johnson & Johnson reported for 2024 q1
SEC form 8
2024-05-01 00:00 ET
Johnson & Johnson published news for 2024 q1
SEC form 8
2024-05-01 00:00 ET
Johnson & Johnson reported for 2024 q1
SEC form 8
2024-05-01 00:00 ET
Johnson & Johnson published news for 2024 q1
SEC form 8
2024-04-16 07:06 ET
Johnson & Johnson published news for 2024 q1
SEC form 8
2024-04-16 07:06 ET
Johnson & Johnson published news for 2024 q1
SEC form 8
2024-04-16 07:06 ET
Johnson & Johnson reported for 2024 q1
SEC form 8
2024-04-16 07:06 ET
Johnson & Johnson published news for 2024 q1
SEC form 10
2024-02-16 16:12 ET
Johnson & Johnson reported for 2023 q4
SEC form 10
2024-02-16 00:00 ET
Johnson & Johnson reported for 2023 q4
SEC form 8
2024-01-23 07:45 ET
Johnson & Johnson published news for 2023 q4
SEC form 8
2024-01-23 07:45 ET
Johnson & Johnson published news for 2023 q4
SEC form 8
2024-01-23 07:45 ET
Johnson & Johnson reported for 2023 q4
SEC form 10
2023-10-27 00:00 ET
Johnson & Johnson reported for 2023 q3
SEC form 8
2023-10-17 07:33 ET
Johnson & Johnson reported for 2023 q3
SEC form 8
2023-08-30 00:00 ET
Johnson & Johnson published news for 2023 q2
SEC form 10
2023-07-31 00:00 ET
Johnson & Johnson reported for 2023 q2
SEC form 6
2023-07-20 07:15 ET
Johnson & Johnson reported for 2023 q2
SEC form 8
2023-07-20 00:00 ET
Johnson & Johnson published news for 2023 q2
SEC form 6
2023-06-26 16:39 ET
Johnson & Johnson published news for 2023 q1
SEC form 6
2023-06-26 16:38 ET
Johnson & Johnson published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
Johnson & Johnson reported for 2023 q1
SEC form 6
2023-04-18 07:29 ET
Johnson & Johnson reported for 2023 q1
SEC form 8
2023-04-18 00:00 ET
Johnson & Johnson reported for 2023 q1
SEC form 6
2023-04-04 16:12 ET
Johnson & Johnson published news for 2023 q1
SEC form 6
2023-03-31 19:29 ET
Johnson & Johnson published news for 2022 q4
SEC form 10
2023-02-16 16:01 ET
Johnson & Johnson reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Johnson & Johnson reported for 2022 q4
SEC form 6
2023-02-14 17:55 ET
Johnson & Johnson published news for 2022 q4
SEC form 6
2023-02-14 16:35 ET
Johnson & Johnson published news for 2022 q4
SEC form 6
2023-01-24 07:44 ET
Johnson & Johnson reported for 2022 q4
SEC form 8
2023-01-24 00:00 ET
Johnson & Johnson reported for 2022 q4
SEC form 6
2022-12-22 16:31 ET
Johnson & Johnson published news for 2022 q3
SEC form 6
2022-11-30 17:38 ET
Johnson & Johnson published news for 2022 q3
SEC form 6
2022-11-01 07:30 ET
Johnson & Johnson published news for 2022 q3
SEC form 10
2022-10-27 16:02 ET
Johnson & Johnson reported for 2022 q3
SEC form 10
2022-10-27 00:00 ET
Johnson & Johnson reported for 2022 q3
SEC form 6
2022-10-18 07:54 ET
Johnson & Johnson published news for 2022 q3
SEC form 8
2022-10-18 00:00 ET
Johnson & Johnson reported for 2022 q3
SEC form 6
2022-09-14 07:10 ET
Johnson & Johnson published news for 2022 q2
SEC form 10
2022-07-29 16:14 ET
Johnson & Johnson reported for 2022 q2
SEC form 10
2022-07-29 00:00 ET
Johnson & Johnson reported for 2022 q2
SEC form 6
2022-07-19 07:59 ET
Johnson & Johnson published news for 2022 q2
SEC form 8
2022-07-19 00:00 ET
Johnson & Johnson reported for 2022 q2
SEC form 6
2022-06-16 16:33 ET
Johnson & Johnson published news for 2022 q1
SEC form 6
2022-06-16 16:31 ET
Johnson & Johnson published news for 2022 q1
SEC form 10
2022-04-29 16:08 ET
Johnson & Johnson reported for 2022 q1
SEC form 6
2022-04-29 16:03 ET
Johnson & Johnson published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Johnson & Johnson reported for 2022 q1
SEC form 6
2022-04-19 07:56 ET
Johnson & Johnson published news for 2022 q1
SEC form 8
2022-04-19 00:00 ET
Johnson & Johnson reported for 2022 q1
SEC form 6
2022-03-16 08:10 ET
Johnson & Johnson published news for 2021 q4
SEC form 10
2022-02-17 16:06 ET
Johnson & Johnson published news for 2021 q4
SEC form 10
2022-02-17 00:00 ET
Johnson & Johnson published news for 2021 q4
SEC form 6
2022-02-15 18:07 ET
Johnson & Johnson published news for 2021 q4
SEC form 6
2022-02-02 16:35 ET
Johnson & Johnson published news for 2021 q4
SEC form 6
2022-01-25 08:00 ET
Johnson & Johnson published news for 2021 q4
SEC form 8
2022-01-25 00:00 ET
Johnson & Johnson published news for 2021 q4
SEC form 6
2022-01-06 16:51 ET
Johnson & Johnson published news for 2021 q4
SEC form 6
2021-11-15 16:57 ET
Johnson & Johnson published news for 2021 q3
SEC form 10
2021-10-29 16:05 ET
Johnson & Johnson published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
Johnson & Johnson published news for 2021 q3
SEC form 6
2021-10-19 08:01 ET
Johnson & Johnson published news for 2021 q3
SEC form 8
2021-10-19 00:00 ET
Johnson & Johnson published news for 2021 q3
SEC form 6
2021-10-12 16:50 ET
Johnson & Johnson published news for 2021 q3
SEC form 6
2021-08-20 16:31 ET
Johnson & Johnson published news for 2021 q2
SEC form 10
2021-07-29 16:07 ET
Johnson & Johnson published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Johnson & Johnson published news for 2021 q2
SEC form 6
2021-07-21 08:00 ET
Johnson & Johnson published news for 2021 q2
SEC form 8
2021-07-21 00:00 ET
Johnson & Johnson published news for 2021 q2
SEC form 6
2021-06-17 16:48 ET
Johnson & Johnson published news for 2021 q1
SEC form 6
2021-06-17 16:40 ET
Johnson & Johnson published news for 2021 q1
SEC form 6
2021-06-01 17:16 ET
Johnson & Johnson published news for 2021 q1
SEC form 10
2021-04-30 16:04 ET
Johnson & Johnson published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Johnson & Johnson published news for 2021 q1
SEC form 6
2021-04-26 16:35 ET
Johnson & Johnson published news for 2021 q1
SEC form 6
2021-04-20 08:02 ET
Johnson & Johnson published news for 2021 q1
SEC form 8
2021-04-20 00:00 ET
Johnson & Johnson published news for 2021 q1
SEC form 6
2021-03-10 08:21 ET
Johnson & Johnson published news for 2020 q4
SEC form 10
2021-02-22 16:36 ET
Johnson & Johnson published news for 2020 q4
SEC form 6
2021-01-26 08:06 ET
Johnson & Johnson published news for 2020 q4
SEC form 6
2020-12-03 16:47 ET
Johnson & Johnson published news for 2020 q3
SEC form 6
2020-11-03 16:45 ET
Johnson & Johnson published news for 2020 q3
SEC form 10
2020-10-23 16:06 ET
Johnson & Johnson published news for 2020 q3
SEC form 6
2020-10-13 07:12 ET
Johnson & Johnson published news for 2020 q3
SEC form 6
2020-10-01 16:22 ET
Johnson & Johnson published news for 2020 q3